Compare Alphabet Inc Class A (GOOGL) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alphabet Inc Class A vs TG Therapeutics Inc — how do they compare? Alphabet Inc Class A trades at $346.26 (market cap $4.20T), while TG Therapeutics Inc trades at $47.68 (market cap $7.58B). The key difference: Alphabet Inc Class A is far larger — about 554.1× TG Therapeutics Inc's market cap, and Alphabet Inc Class A pays a 0.26% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| GOOGL | TGTX | |
|---|---|---|
Market Cap | $4.20T | $7.58B |
Sector | Media | Health |
52-Week High | $402.62 | $59.06 |
52-Week Low | $199.32 | $26.94 |
Enterprise Value | $4.08T | $7.78B |
Dividend Yield | 0.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOGL) trades at $346.36, up 0.74% with strong fundamental performance including 32.8% net profit margin and consistent earnings beats. The stock shows bearish technical signals with support at $337 and resistance at $349, while maintaining robust cash flow generation of $164.71B from operations. Recent news highlights AI-driven growth opportunities through partnerships with Anthropic and Intel, though technical indicators suggest near-term caution.
Alphabet presents a compelling long-term investment with 85% analyst buy ratings and $426.28 price target, representing 23% upside. Strong revenue growth to $402.84B and expanding margins support valuation, though regulatory risks and technical bearishness warrant monitoring. The company's AI infrastructure investments and YouTube price increases provide growth catalysts.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
